Citations (21)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (5)
Eugene McLaurin, Mark Bergmann, Abhijit Narvekar, Adeniyi Adewale, Paul Gomes & Gail Torkildsen. (2017) Pooled analysis of two studies evaluating efficacy and safety of olopatadine hydrochloride 0.77% in patients with allergic conjunctivitis. Clinical Ophthalmology 11, pages 1089-1097.
Read now
Read now
Stacey Ackerman, Francis D’Ambrosio$suffix/text()$suffix/text(), Jack V Greiner, Linda Villanueva, Joseph B Ciolino & David A Hollander. (2013) A multicenter evaluation of the efficacy and duration of action of alcaftadine 0.25% and olopatadine 0.2% in the conjunctival allergen challenge model. Journal of Asthma and Allergy 6, pages 43-52.
Read now
Read now
Rengin Aslıhan Kurt, Ömür Ucakhan-Gündüz & Kaan Gündüz. (2010) Olopatadine 0.1% and 0.2% ophthalmic solution for the management of ocular allergy. Expert Review of Ophthalmology 5:3, pages 287-296.
Read now
Read now
Andrea Leonardi & Luigi Quintieri. (2010) Olopatadine: a drug for allergic conjunctivitis targeting the mast cell. Expert Opinion on Pharmacotherapy 11:6, pages 969-981.
Read now
Read now
Arthur B Epstein, Peter T Van Hoven, Alan Kaufman & Warner W Carr. (2009) Management of allergic conjunctivitis: an evaluation of the perceived comfort and therapeutic efficacy of olopatadine 0.2% and azelastine 0.05% from two prospective studies. Clinical Ophthalmology 3, pages 329-336.
Read now
Read now
Articles from other publishers (16)
Najam A. Sharif. 2022. Handbook of Basic and Clinical Ocular Pharmacology and Therapeutics. Handbook of Basic and Clinical Ocular Pharmacology and Therapeutics
403
422
.
Eugene B. McLaurin, David Evans, Carolyn S. Repke, Michelle A. Sato, Paul J. Gomes, Erin Reilly, Nysha Blender, Fabiana Q. Silva, Srilatha Vantipalli, Jamie L. Metzinger, Andrea Gibson & Michael H. Goldstein. (2021) Phase 3 Randomized Study of Efficacy and Safety of a Dexamethasone Intracanalicular Insert in Patients With Allergic Conjunctivitis. American Journal of Ophthalmology 229, pages 288-300.
Crossref
Crossref
Najam A. Sharif. (2020) Discovery to Launch of Anti-allergy (Emadine; Patanol/Pataday/Pazeo) and Anti-glaucoma (Travatan; Simbrinza) Ocular Drugs, and Generation of Novel Pharmacological Tools Such as AL-8810. ACS Pharmacology & Translational Science 3:6, pages 1391-1421.
Crossref
Crossref
Yushun Xue, Wenzhi Zhang, Yan Lei & Minyan Dang. (2020) Novel Polyvinyl Pyrrolidone–Loaded Olopatadine HCl–Laden Doughnut Contact Lens to Treat Allergic Conjunctivitis. Journal of Pharmaceutical Sciences 109:5, pages 1714-1724.
Crossref
Crossref
DeGaulle I. Chigbu, Pooja Jain & Zafar K. Khan. 2020. Advanced Concepts in Human Immunology: Prospects for Disease Control. Advanced Concepts in Human Immunology: Prospects for Disease Control
229
277
.
Hakika Erdogan & Ozlem Cam. (2018) The Effect Of Topical Antihistamines Used Single Dose Daily in Allergic Conjunctivitis. The Open Ophthalmology Journal 12:1, pages 330-337.
Crossref
Crossref
Matthew L. Fidler, Abayomi Ogundele, David Covert & Ramesh Sarangapani. (2018) Projected 24-hour post-dose ocular itching scores post-treatment with olopatadine 0.7% versus 0.2%. Journal of Pharmacokinetics and Pharmacodynamics 45:4, pages 593-605.
Crossref
Crossref
Pranav Gupta, Etti Goyal & Jaya Devendra. (2016) Comparative Study of 0.1% Olopatadine vs 0.05% Cyclosporine in Patients of Recalcitrant Vernal Keratoconjunctivitis. International Journal of Advanced and Integrated Medical Sciences 1:4, pages 139-142.
Crossref
Crossref
Tao Zhang, Deirdre Frances Finn, James William Barlow & John Jarlath Walsh. (2016) Mast cell stabilisers. European Journal of Pharmacology 778, pages 158-168.
Crossref
Crossref
Warner Carr, Jack Schaeffer & Eric Donnenfeld. (2016) Treating Allergic Conjunctivitis: A Once-daily Medication that Provides 24-hour Symptom Relief. Allergy & Rhinology 7:2, pages ar.2016.7.0158.
Crossref
Crossref
Soo-Wan Choi, Ju-Hee Ryu, Ji-Sun Park, Myung-Jae Lee, Sung-Vin Yim & Kyung-Tae Lee. (2015) Development and validation for the determination of olopatadine in human plasma by liquid chromatography–tandem mass spectrometry: application to a bioequivalence study of Ilhwa Allotadine tablet (olopatadine HCl 5 mg). Journal of Pharmaceutical Investigation 45:3, pages 285-292.
Crossref
Crossref
Virginia Miraldi Utz & Aaron R. Kaufman. (2014) Allergic Eye Disease. Pediatric Clinics of North America 61:3, pages 607-620.
Crossref
Crossref
Thomas R. Walters, Damien F. Goldberg, James H. Peace & James A. Gow. (2014) Bromfenac Ophthalmic Solution 0.07% Dosed Once Daily for Cataract Surgery. Ophthalmology 121:1, pages 25-33.
Crossref
Crossref
Punchama Pacharn & Pakit Vichyanond. (2013) Immunomodulators for conjunctivitis. Current Opinion in Allergy & Clinical Immunology 13:5, pages 550-557.
Crossref
Crossref
Mark B. Abelson, James T. McLaughlin & Paul J. Gomes. (2011) Antihistamines in Ocular Allergy: Are They All Created Equal?. Current Allergy and Asthma Reports 11:3, pages 205-211.
Crossref
Crossref
DeGaulle I. Chigbu. (2009) The management of allergic eye diseases in primary eye care. Contact Lens and Anterior Eye 32:6, pages 260-272.
Crossref
Crossref